Guest Editor: Pellegrino Musto HOW FIRST-LINE THERAPY IS CHANGING IN NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS. Mediterr J Hematol Infect Dis 2025, 17 (1), e2025025. https://doi.org/10.4084/MJHID.2025.025.